세계의 췌장암 치료 및 진단 시장 : 유형별, 지역별

Pancreatic Cancer Therapeutics and Diagnostic Market, By Type (Treatment (Targeted Therapies, Chemotherapy, Surgery, and Other Treatments)), By Geography (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)

US $ 4,500 ￦ 6,286,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,000 ￦ 9,778,000

PDF (Multi User License)

PDF 보고서를 동일 사업장에서 7명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,969,000

PDF (Enterprise User License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

췌장암 치료 및 진단 시장은 2025년에는 36억 8,960만 달러, 2032년에는 60억 3,930만 달러에 이를 것으로 예측되며, 2025-2032년 연평균 복합 성장률(CAGR) 7.3%로 성장할 전망입니다.

보고서 범위		보고서 상세
기준 연도	2024년	2025년 시장 규모	36억 8,960만 달러
실적 데이터	2020-2024년	예측 기간	2025-2032년
예측 기간 : 2025-2032년	7.30%	2032년 금액 예측	60억 3,930만 달러

췌장암은 췌장 세포에 생기는 암입니다. 췌장암은 췌장 세포의 변화(돌연변이)로 인해 통제할 수 없을 정도로 증식하여 발생합니다. 암은 초음파 검사, 컴퓨터단층촬영(CT) 검사, 자기공명영상법(MRI) 검사, 양전자방사선단층촬영(PET) 검사 등으로 진단할 수 있습니다. 치료에는 수술, 방사선 치료, 화학요법 또는 이들의 조합이 포함될 수 있습니다.

시장 역학

췌장암 발병률 및 유병률 증가, 새로운 치료법 개발 증가, 노인 인구 증가, 안전하고 효과적인 치료법에 대한 수요 증가, 사람들의 인식 증가는 세계 췌장암 치료 및 진단 시장의 성장을 증가시킬 것으로 예상되는 주요 요인입니다.

예를 들어, 2021년 1월 Myriad Genetics Inc.와 Illumina Inc.는 췌장암 검출에 사용할 수 있는 myChoice 동반 진단 테스트의 키트 기반 버전을 국제 시장을 위해 공동 개발했습니다.

또한, 2020년 9월 인도 의학연구위원회(ICMR)-국립암예방연구센터(NICPR)는 'India against Cancer'를 주제로 췌장암을 포함한 암의 인식 제고, 예방, 치료에 주안점을 두고 인도의 주요 암에 대한 정보를 제공하는 포털사이트인 www.cancerindia.org.

본 조사의 주요 특징

• 세계의 췌장암 치료 및 진단제 시장을 상세하게 분석하여 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모와 연평균 성장률(CAGR)을 조사 분석하여 전해드립니다.
• 이 보고서는 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 매개 변수를 기반으로 세계 췌장암 치료 및 진단 의약품 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 췌장암 치료 및 진단약 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 규제 시나리오
• 제품 발매 및 승인
• PEST 분석
• Porter's Five Forces 분석
• 인수합병(M&A) 시나리오

제4장 세계의 췌장암 치료 및 진단 시장, 유형별, 2020-2032년

• 서론
• 치료
• 진단

제5장 세계의 췌장암 치료 및 진단 시장, 지역, 2020-2032년

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동
• 아프리카

제6장 경쟁 구도

• F. Hoffmann-La Roche AG
• Merck KgaA
• Apexigen Inc.
• Immunovia AB
• Viatris Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb
• Novartis AG
• Pfizer Inc.
• Myriad Genetics Inc.
• Canon Medical Systems Corporation
• FUJIFILM Holdings Corporation
• Boston Scientific Corporation
• Rafael Holdings Inc.(Rafael Pharmaceuticals)

제7장 섹션

• 조사 방법
• 출판사에 대해

LSH

영문 목차

영문목차

Pancreatic Cancer Therapeutics And Diagnostic Market is estimated to be valued at USD 3,689.6 Mn in 2025 and is expected to reach USD 6,039.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 3,689.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.30%	2032 Value Projection:	USD 6,039.3 Mn

Pancreatic cancer is cancer that forms in the cells of the pancreas. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control. The cancer can be diagnosed with the help of ultrasound, computerized tomography (CT) scans, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. Treatment may include surgery, radiation, chemotherapy, or a combination of these.

Market Dynamics:

Rise in incidence and prevalence of pancreatic cancer, rise in development of novel therapeutics, growing geriatric population, increase in demand for safe and effective therapeutics, and increase in awareness among people are major factors expected to augment growth of the global pancreatic cancer therapeutics and diagnostic market.

For instance, in January 2021, Myriad Genetics Inc. and Illumina Inc. collaborated to develop a kit-based version of the myChoice companion diagnostic test for international markets, which can be used to detect pancreatic cancer.

Moreover, in September 2020, the Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research (NICPR) launched www.cancerindia.org with the theme 'India against Cancer, a portal that provides information on the leading cancers in India with the major focus on awareness, prevention, and treatment of cancers, including pancreatic cancer.

Key features of the study:

• This report provides in-depth analysis of the global pancreatic cancer therapeutics and diagnostic market, and provides market size (USD Million) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global pancreatic cancer therapeutics and diagnostic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include F Hoffmann-La Roche AG, Merck KgaA, Apexigen Inc., Immunovia AB, Viatris Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Myriad Genetics Inc., Canon Medical Systems Corporation, FUJIFILM Holdings Corporation, Boston Scientific Corporation, and Rafael Holdings Inc. (Rafael Pharmaceuticals), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global pancreatic cancer therapeutics and diagnostic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pancreatic cancer therapeutics and diagnostic market.

Detailed Segmentation:

• Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type:
  • Treatment
  • Diagnostics
• Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • Latin America
• Company Profiles:
  • F.Hoffmann-La Roche AG
  • Merck KgaA
  • Apexigen Inc.
  • Immunovia AB
  • Viatris Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb
  • Novartis AG
  • Pfizer Inc.
  • Myriad Genetics Inc.
  • Canon Medical Systems Corporation
  • FUJIFILM Holdings Corporation
  • Boston Scientific Corporation
  • Rafael Holdings Inc. (Rafael Pharmaceuticals)

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Geography
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Rise in incidence and prevalence of pancreatic cancer
  • High cost associated with diagnosis and treatments
  • Increase in demand for safe and effective therapeutics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Treatment
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)
• Diagnostics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(USD Mn)

5. Global Pancreatic Cancer Therapeutics and Diagnostic Market, By Geography, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • GCC Country
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(USD Mn)
    • South Africa
    • North Africa
    • Central Africa

6. Competitive Landscape

• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck KgaA
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Apexigen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Immunovia AB
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Viatris Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
• Strategies
  • Canon Medical Systems Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• FUJIFILM Holdings Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Boston Scientific Corporation
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Rafael Holdings Inc. (Rafael Pharmaceuticals)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

7. Section

• Research Methodology
• About us

관련자료